New taxanes in development

Bibliography

• Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44
   PubMed Web of Science ®Google Scholar
• Schnitzer JE, Oh P. Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins. J Biol Chem 1994;269:6072-82
   PubMed Web of Science ®Google Scholar
• Desai N, Soon-Shiong P, Yao Z. Evidence of a novel transporter, mechanism for a cremophor-free, protein-engineered paclitaxel (ABI-007) and in vivo antitumor activity in MX-1 human breast tumor xenograft model. Breast Cancer Res Treat 2002;76:S131
   Google Scholar
• Ibrahim NK, Samuels B, Page R, et al. Multicenter Phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23:6019-26
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803
   PubMed Web of Science ®Google Scholar
• Li C. Poly (L-glutamic acid) – anticancer drug conjugates. Adv Drug Deliv Rev 2002;54:695-713
   PubMed Web of Science ®Google Scholar
• Singer JW, Baker B, De Vries P, et al. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [Xyotax], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv Exp Med Biol 2003;519:81-99
   PubMed Web of Science ®Google Scholar
• Boddy AV, Plummer ER, Todd R, et al. A Phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res 2005;11:7834-40
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Aghajanian C, Dizon D, et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol 2004;22:4523-31
   PubMed Web of Science ®Google Scholar
• Richards DA, Richards P, Bodkin D, et al. Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a Phase II study. Clin Lung Cancer 2005;7:215-20
   PubMed Web of Science ®Google Scholar
• Langer C, O'Byrne K, Ross H, et al. XYOTAX (TM)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC): the stellar 3 Phase III study. Lung Cancer 2005;49:S36
   Google Scholar
• O'Brien M, Sandler A, Popovich A, et al. XYOTAX (TM) vs gemcitabine or vinorelbine for the treatment of performance status (PS) 2 patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC): the STELLAR 4 Phase III study. Lung Cancer 2005;49:S37
   Google Scholar
• Cella D, Cashy J. Symptom relief and quality of life (QOL) in PS2 patients with non-small cell lung cancer (NSCLC) subsequent to treatment with paclitaxel poliglumex (XYOTAX (TM)): Phase 3 trial results. Lung Cancer 2005;49:S277-8
   Google Scholar
• Bradley MO, Webb NL, Anthony FH, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 2001;7:3229-38
   PubMed Web of Science ®Google Scholar
• Wolff AC, Donehower RC, Carducci MK, et al. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 2003;9:3589-97
   PubMed Web of Science ®Google Scholar
• Payne M, Ellis P, Dunlop D, et al. DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a Phase II open-label multicenter trial. J Thorac Oncol 2006;1:984-90
   PubMed Web of Science ®Google Scholar
• Jones RJ, Hawkins RE, Eatock MM, et al. A Phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol 2008;61:435-41
   PubMed Web of Science ®Google Scholar
• Modiano MR, Houston S, Sacage P, et al. Efficacy of DHA-paclitaxel (TXP) in malignant melanoma [Abstract]. Proc Am Soc Clin Oncol 2003;22:2891
   Web of Science ®Google Scholar
• Gelmon KA, Latreille J, Tolcher A, et al. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol 2000;18:4098-108
   PubMed Web of Science ®Google Scholar
• Bissery MC. Preclinical evaluation of new taxoids. Curr Pharm Des 2001;7:1251-7
   PubMed Web of Science ®Google Scholar
• Kurata T, Shimada Y, Tamura T, et al. Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors. J Clin Oncol 2000;18:3164-71
   PubMed Web of Science ®Google Scholar
• Sessa C, Cuvier C, Caldiera S, et al. Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann Oncol 2002;13:1140-50
   PubMed Web of Science ®Google Scholar
• Dieras V, Valero V, Limentani S, et al. Multicenter, non-randomized Phase II study with RPR109881 in taxane-exposed metastatic breast cancer (MBC) patients (pts): final results. J Clin Oncol 2005;23:20S
   Google Scholar
• Sampath D, Discafani CM, Loganzo F, et al. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol Cancer Ther 2003;2:873-84
   PubMed Web of Science ®Google Scholar
• Lockhart AC, Bukowski R, Rothenberg ML, et al. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors. Cancer Chemother Pharmacol 2007;60:203-9
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Shapiro M, Carducci K, et al. Phase I trial of a potent novel taxane, TL00139 (MAC-321), in patients with advanced malignant solid tumors [Abstract]. Proc Am Soc Clin Oncol 2003;22:527
   Google Scholar
• Bourbouloux E, Campone M, Vermorken JB, et al. Phase I study of intravenous (IV) milataxel in adult patients with advanced malignant tumors. J Clin Oncol 2006;24:88S
   Google Scholar
• Mekhail T, Serwatowski P, Dudek A, et al. A Phase II study of intravenous (IV) milataxel (M) for the treatment of non-small cell lung cancer (NSCLC) refractory to platinum-based therapy. J Clin Oncol 2006;24:388S
   Google Scholar
• Ramanathan RK, Picus J, Raftopoulos H, et al. A Phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemother Pharmacol 2008;61:453-8
   PubMed Web of Science ®Google Scholar
• Helson L, Ferrara J, Jones M, McChesney J. NBT-287, a third generation taxane analog, and paclitaxel resistance due to MDR-1 and mutant tubulin. J Clin Oncol 2004;22:223S
   Google Scholar
• Jones ME, Bell CB, Schiemann BJ, et al. Biological characterization of TPI 287 – a novel third generation taxane analog. Clin Cancer Res 2005;11:9089S
   Web of Science ®Google Scholar
• Modiano MR, Plezia P, Baram J, et al. A Phase I study of TPI 287, a third generation taxane, administered every 21 days in patients with advanced cancer [Abstract]. Proc Am Soc Clin Oncol 2007;25:2569
   Google Scholar
• Longley RE, Fasciani G, Sander L, Holton RA. In vitro mechanism of action studies with the taxane analog, TL-310 [Abstract]. Proc Am Assoc Cancer Res 2005;46:46
   Google Scholar
• Longley RE, Clement C, Metts L, Holton RA. In vivo efficacy of TL-310; a new, orally active taxane analog [Abstract]. Proc Am Assoc Cancer Res 2006;46:47
   Google Scholar
• Glasspool RM, Boddy AV, Evans TR, et al. A Phase I study of a novel taxane, TL310, orally administered every week in patients (pts) with advanced solid tumors [Abstract]. Proc Am Soc Clin Oncol 2007;25:2544
   Google Scholar
• Mastalerz H, Cook D, Fairchild CR, et al. The discovery of BMS-275183: an orally efficacious novel taxane. Bioorg Med Chem 2003;11:4315-23
   PubMed Web of Science ®Google Scholar
• Rose WC, Long BH, Fairchild CR, et al. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res 2001;7:2016-21
   PubMed Web of Science ®Google Scholar
• Rose WC, Wild R. Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts. Clin Cancer Res 2004;10:7413-7
   PubMed Web of Science ®Google Scholar
• Broker LE, de Vos FY, van Groeningen CJ, et al. Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. Clin Cancer Res 2006;12:1760-7
   PubMed Web of Science ®Google Scholar
• Broker LE, Veltkamp SA, Heath EI, et al. A Phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clin Cancer Res 2007;13:3906-12
   PubMed Web of Science ®Google Scholar
• Altstadt TJ, Fairchild CR, Golik J, et al. Synthesis and antitumor activity of novel C-7 paclitaxel ethers: discovery of BMS-184476. J Med Chem 2001;44:4577-83
   PubMed Web of Science ®Google Scholar
• Rose WC, Fairchild C, Lee FY. Preclinical antitumor activity of two novel taxanes. Cancer Chemother Pharmacol 2001;47:97-105
   PubMed Web of Science ®Google Scholar
• Kim JS, Amorino GP, Pyo H, et al. The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. Int J Radiat Oncol Biol Phys 2001;51:525-34
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Aylesworth C, Hammond LA, et al. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol 2001;19:2493-503
   PubMed Web of Science ®Google Scholar
• Plummer R, Ghielmini M, Calvert P, et al. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. Clin Cancer Res 2002;8:2788-97
   PubMed Web of Science ®Google Scholar
• Sun W, Stevenson JP, Gallagher ML, et al. Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days. Clin Cancer Res 2003;9:5221-7
   PubMed Web of Science ®Google Scholar
• Bilenker JH, Stevenson JP, Gallagher ML, et al. Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days. Br J Cancer 2004;91:213-8
   PubMed Web of Science ®Google Scholar
• Sessa C, Perotti A, Salvatorelli E, et al. Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. Eur J Cancer 2004;40:563-70
   PubMed Web of Science ®Google Scholar
• Camps C, Felip E, Sanchez JM, et al. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol 2005;16:597-601
   PubMed Web of Science ®Google Scholar
• Bergh J, Lidbrink E, Albertsson M, et al. A randomized Phase II study of two different schedules of BMS-184476-a novel taxane, in patients with previously antracycline treated metastatic breast cancer [Abstract]. Proc Am Soc Clin Oncol 2002;21:2010
   Google Scholar
• Gonzalez E, Bajetta E, Buzaid A, et al. Phase II study of novel taxane BMS-184476 in previously treated patients with metastatic non-choroidal melanoma (MM) [Abstract]. Proc Am Soc Clin Oncol 2001;20:1383
   Web of Science ®Google Scholar
• Boyer MJ, Moore M, Leichman L, et al. Phase II study of novel taxane BMS-184476 in previously treated patients with advanced adenocarcinoma involving the stomach or gastroesophageal (GE) junction [Abstract]. Proc Am Soc Clin Oncol 2002;21:591
   Web of Science ®Google Scholar
• Poole CJ, Thomas H, Jayson G, et al. Phase II clinical trial of BMS-184476, a novel taxane, administered days 1 and 8 every 28 days in patients (pts) with relapsed epithelial ovarian cancer (EOC) previously treated with platinum and paclitaxel-based chemotherapy [Abstract]. Proc Am Soc Clin Oncol 2002;21:832
   Google Scholar
• Advani R, Fisher GA, Lum BL, et al. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res 2003;9:5187-94
   PubMed Web of Science ®Google Scholar
• Garrett CR, Fishman MN, Rago RR, et al. Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies. Clin Cancer Res 2005;11:3335-41
   PubMed Web of Science ®Google Scholar
• Fishman MN, Garrett CR, Simon GR, et al. Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies. Clin Cancer Res 2006;12:523-8
   PubMed Web of Science ®Google Scholar
• Ojima I, Park YH, Sun CM, et al. Structure-activity relationships of new taxoids derived from 14 beta-hydroxy-10-deacetylbaccatin III. J Med Chem 1994;37:1408-10
   PubMed Web of Science ®Google Scholar
• Jordan MA, Ojima I, Rosas F, et al. Effects of novel taxanes SB-T-1213 and IDN5109 on tubulin polymerization and mitosis. Chem Biol 2002;9:93-101
   PubMed Web of Science ®Google Scholar
• Distefano M, Scambia G, Ferlini C, et al. Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int J Cancer 1997;72:844-50
   PubMed Web of Science ®Google Scholar
• Nicoletti MI, Colombo T, Rossi C, et al. IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Res 2000;60:842-6
   PubMed Web of Science ®Google Scholar
• Cassinelli G, Lanzi C, Supino R, et al. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer. Clin Cancer Res 2002;8:2647-54
   PubMed Web of Science ®Google Scholar
• Ramnath N, Hamm J, Schwartz G, et al. A Phase I and pharmacokinetic study of BAY59: a novel taxane. Oncology 2004;67:123-9
   PubMed Web of Science ®Google Scholar
• Laurence V, Pierga JY, Beuzeboc P, et al. A Phase I and pharmacokinetic study of a novel taxane BAY 59-8862 with a weekly schedule [Abstract]. Proc Am Soc Clin Oncol 2003;22:647
   Google Scholar
• Tonkin K, Herbert H, Lathia C, et al. A Phase I and pharmacokinetic study of a novel oral taxane BAY 59-8862 in solid tumors [Abstract]. Proc Am Soc Clin Oncol 2003;22:965
   Google Scholar
• Amadori D, Santoro A, Hoffken K, et al. A Phase II trial of a novel taxane BAY 59-8862 in patients with advanced taxane-resistant breast cancer [Abstract]. Proc Am Soc Clin Oncol 2003;22:176
   Google Scholar
• Gurtler JS, Von Pawel J, Spiridonidis CH, et al. An uncontrolled Phase II study evaluating anti-tumor efficacy and safety of ortataxel (BAY 59-8862) in patients with taxane-resistant non-small cell lung cancer. J Clin Oncol 2004;22:650S
   Google Scholar
• Shionoya M, Jimbo T, Kitagawa M, et al. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 2003;94:459-66
   PubMed Web of Science ®Google Scholar
• Moore MR, Jones C, Harker G, et al. Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer. J Clin Oncol 2006;24:168S
   Google Scholar
• Szczesna A, Milanowski E, Juhász E, et al. A Phase II study of DJ-927 administered orally once every three weeks as second line therapy to subjects with locally advanced or metastatic non small cell lung cancer (NSCLC) after failure of platinum-based non-taxane regimen. J Clin Oncol 2006;24(18S):17006
   Google Scholar
• Mozzetti S, Ferlini C, Concolino P, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005;11:298-305
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Zannoni GF, Martinelli E, et al. Class III {beta}-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006;12:2774-9
   PubMed Web of Science ®Google Scholar
• Seve P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 2007;13:994-9
   PubMed Web of Science ®Google Scholar
• Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 2005;16(Suppl 4):iv14-9
   PubMedGoogle Scholar
• Urano N, Fujiwara Y, Doki Y, et al. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 2006;28:375-81
   PubMed Web of Science ®Google Scholar
• Lee KM, Cao D, Itami A, et al. Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology 2007;51:539-46
   PubMed Web of Science ®Google Scholar